Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy
In conclusion, our outcomes recommend the Pd(II) complex as a new optimistic candidate for tumor therapy after further studies for validation. (Source: Investigational New Drugs)
Source: Investigational New Drugs - March 30, 2022 Category: Drugs & Pharmacology Source Type: research
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells
This study investigates the growth inhibitory efficacy of poly-guanidine (GuaDex), with an affinity for sialic acid (Sia). Glioma cell cultures and patient-derived glioma cell lines (PDGCLs) expressing Prominin-1 (CD133) were used. Human fibroblasts and astrocyte-derived cells were used as controls. Temozolomide (standard GBM drug, TMZ) and DMSO were used as a comparison. GuaDex at 1–10 µM concentrations, were incubated for 3.5–72 h and with PDGCLs cells for 6–24 h . The cytotoxicity was estimated with a fluorometric cytotoxicity assay (FMCA). Fluorescence-labelled GuaDex was used to study the cell interactio...
Source: Investigational New Drugs - March 21, 2022 Category: Drugs & Pharmacology Source Type: research
The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells
AbstractOur group recently demonstrated that K858, an inhibitor of motor kinesin Eg5, has important antiproliferative and apoptotic effects on breast cancer, prostatic cancer, melanoma and glioblastoma cells. Since high levels of kinesin Eg5 expression have been correlated with a poor prognosis in laryngeal carcinoma, we decided to test the anticancer activity of K858 toward this tumor, which belongs to the group of head and neck squamous cell carcinomas (HNSCCs). These cancers are characterized by low responsiveness to therapy. The effects of K858 on the proliferation and assembly of mitotic spindles of three human HNSCC ...
Source: Investigational New Drugs - March 21, 2022 Category: Drugs & Pharmacology Source Type: research
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
AbstractChemoradiotherapy (CRT) for locally-advanced head and neck squamous cell carcinoma (LA-HSNCC) yields 5-year survival rates near 50% despite causing significant toxicity. Dichloroacetate (DCA), a pyruvate dehydrogenase kinase metabolic inhibitor, reduces tumor lactate production and has been used in cancer therapy previously. The safety of adding this agent to CRT is unknown. Our randomized, placebo-controlled, double-blind phase II study added DCA to cisplatin-based CRT in patients with LA-HNSCC. The primary endpoint was safety by adverse events (AEs). Secondary endpoints compared efficacy via 3-month end-of-treatm...
Source: Investigational New Drugs - March 21, 2022 Category: Drugs & Pharmacology Source Type: research
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis
Conclusions. Mifamurtide was well tolerated in a Greek osteosarcoma population, including patients older than 30 years. The small sample size and the non-comparative design do not allow drawing conclusions on the drug benefit in terms of survival. (Source: Investigational New Drugs)
Source: Investigational New Drugs - March 21, 2022 Category: Drugs & Pharmacology Source Type: research
Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer
AbstractPancreatic cancer remains one of the most lethal cancers largely due to the inefficient delivery of therapeutics. Nanomaterials have been extensively investigated as drug delivery platforms, showing improved drug pharmacodynamics and pharmacokinetics. However, their applications in pancreatic cancer have not yet been successful due to limited tumor delivery caused by dense tumor stroma and distorted tumor vasculatures. Meanwhile, smaller-sized nanomaterials have shown improved tumor delivery and retention in various tumors, including pancreatic tumors, suggesting their potential in enhancing drug delivery. An ultra...
Source: Investigational New Drugs - March 15, 2022 Category: Drugs & Pharmacology Source Type: research
An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer
Conclusion. The RP2D of FTD/TPI combined with irinotecan was determined to be Level 1B; this level was associated with manageable hematologic toxicities and feasible non-hematologic toxicities. Further evaluation of the efficacy of RP2D treatment is necessary. (Source: Investigational New Drugs)
Source: Investigational New Drugs - March 12, 2022 Category: Drugs & Pharmacology Source Type: research
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
(Source: Investigational New Drugs)
Source: Investigational New Drugs - February 28, 2022 Category: Drugs & Pharmacology Source Type: research
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4
Conclusion Our results indicate that IL-10 contributes to the resistance of ENKTL cells via ABCC4 and that IL-10 regulates the JAK/STAT signaling pathway in YT and NK-92 cells. (Source: Investigational New Drugs)
Source: Investigational New Drugs - February 28, 2022 Category: Drugs & Pharmacology Source Type: research
The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
Conclusions. SK-UT-1 was confirmed as a representative model of uterine leiomyosarcoma and CX-5461 has significant potential as a novel adjuvant for this rare cancer. (Source: Investigational New Drugs)
Source: Investigational New Drugs - February 24, 2022 Category: Drugs & Pharmacology Source Type: research
A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects
Conclusion. The 90% CI value of Cmax and AUC0-t for QLHER2/Herceptin ratio ranged between 80.0% –125.00%, indicating that QLHER2 was bioequivalent to Herceptin. These results support further evaluation of QLHER2. Trial registration number: ChiCTR2000041577 and ChiCTR2100041802. Date of registration: 30th December, 2020 and 5th January 2021. (Source: Investigational New Drugs)
Source: Investigational New Drugs - February 21, 2022 Category: Drugs & Pharmacology Source Type: research
The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients
Conclusion Iodine-125 seed implantation significantly shortened the average length of hospital stay and indwelling catheter time compared with RP, and the haemoglobin level was significantly higher in the PI group than in the RP group; however, the maximum urine flow rate was lower after of PI than after RP. These two methods showed similar BRFS rates among prostate cancer patients. (Source: Investigational New Drugs)
Source: Investigational New Drugs - February 12, 2022 Category: Drugs & Pharmacology Source Type: research
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
Conclusions. The MTD and RP2D could not be established as the study closed early due to the absence of a dose –response relationship and non-optimal PK profile. No further clinical development of M3541 was pursued. (Trial registration number ClinicalTrials.gov NCT03225105. Registration date July 21, 2017). (Source: Investigational New Drugs)
Source: Investigational New Drugs - February 12, 2022 Category: Drugs & Pharmacology Source Type: research
Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study
Conclusion. Orelabrutinib-based regimens were efficacious and well-tolerated in patients with CNSL. These combined therapies offer a new potential therapeutic strategy for patients with CNSL. (Source: Investigational New Drugs)
Source: Investigational New Drugs - February 9, 2022 Category: Drugs & Pharmacology Source Type: research
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Conclusion. During the conduct of the study, management of frequent infusion-related reactions, skin toxicities, and mucosal disorders, which are indicative of HER inhibition, necessitated multiple protocol amendments. The investigators, in concert with the Sponsor, agreed that achieving a tolerated regimen w ith acceptable target saturation was unlikely.Trial registry:www.clinicaltrials.gov; NCT02906670 (September 20, 2016). (Source: Investigational New Drugs)
Source: Investigational New Drugs - February 3, 2022 Category: Drugs & Pharmacology Source Type: research
